**AMSTERDAM, NETHERLANDS – October 20, 2016 –** Synaffix BV announced today it has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect™ and HydraSpace™ site-specific antibody-drug conjugate technologies. Under the terms of the agreement, ADC Therapeutics has been granted a single-target license for one of its preclinical programs and has also been granted an option to take a limited number of additional single-target licenses for potential future programs.
Floris van Delft, CSO at Synaffix said,
“We are delighted that ADC Therapeutics has recognized the value of our proprietary antibodydrug
conjugate technologies and has elected to incorporate Synaffix technology into one
of its preclinical programs.”
“The experience of Synaffix and its partners has consistently confirmed that,
in preclinical models, our proprietary GlycoConnect™ and HydraSpace™ technologies
significantly improved both efficacy and safety as compared to other mainstream site-specific
conjugation approaches.”
“We look forward to working closely with the ADC Therapeutics team to advance these
promising therapeutics to the patients who need them.”
Synaffix is eligible to receive upfront, milestone and royalty payments on a per-target basis.
About GlycoConnect™ and HydraSpace™
The Synaffix technology platforms include GlycoConnect™, the site-specific and stable antibody
conjugation technology that involves proprietary enzymes and metal-free click conjugation
reagents, and HydraSpace™, the antibody-drug conjugate enhancing spacer technology.
GlycoConnect™ was shown to be capable of significantly enhancing the therapeutic index of an
antibody-drug conjugate on its own. The highly polar properties of HydraSpace™ improve the
solubility and stability of the payload and the resulting antibody-drug conjugate product, thus
enhancing further the therapeutic index of the antibody-drug conjugate.
Both technologies have demonstrated compatibility with all antibody-drug conjugate payload
classes and all IgG isotypes without requiring antibody engineering.
About Synaffix BV
Founded in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively
focused on the continued advancement of best-in-class ADC technology platforms. As a leading
innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our
vision is to become the preferred partner in the development of these complex biological
therapeutics and realize our ambition – connect to cure™. Synaffix is backed by a top tier, life
science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and
M Ventures, the strategic corporate venture capital fund of Merck KGaA, Darmstadt, Germany.
For more information, please visit the website at www.synaffix.com.
Synaffix BV Contact
Anthony DeBoer
Director, Business Development
Tel: +31 620 773 194
bd@synaffix.com
